Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-26
2005-04-26
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S023500, C536S024100, C424S184100, C424S185100, C424S198100, C424S278100, C435S320100
Reexamination Certificate
active
06884785
ABSTRACT:
The present invention provides compostions and methods for the prevention or treatment of autoimmune disorders. In particular, the invention methods utilize genetic material encoding at least a portion of an autoreactive epitope that, upon administration to a subject, acts to modulate the immune system thereby ameliorating conditions associated with an autoreactive antigen.
REFERENCES:
patent: 5891435 (1999-04-01), Muir et al.
patent: 5951976 (1999-09-01), Segal
patent: 6207159 (2001-03-01), Kaufman et al.
patent: 6313272 (2001-11-01), Greve et al.
patent: WO 9506718 (1995-03-01), None
patent: WO 9521926 (1995-08-01), None
patent: WO 9745144 (1997-04-01), None
patent: WO 9746253 (1997-12-01), None
patent: WO 9824908 (1998-06-01), None
patent: WO 0020457 (2000-04-01), None
Tokui et al. Suppressive effect on the development of insulin-dependent diabetes mellitus in nonobese diabetic mice by intramuscular injection of plasmid DNA expressing glutamic acid decarboxylase (GAD) adn interleukin-4 (IL-4). Bunshi Tonyobyogaku Vo.*
Ally et al. Prevention of autoimmune disease by retroviral-mediated gene therapy. J. Immunol. vol. 155:5404-5408, Nov. 1995.*
Prud'homme et al. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/lgG1 protein. Gene Therapy vol. 6:771-777, May 1999.*
Giannoukakis et al. Perspectives in Diabetes: Targeting autoimmune diabetes with gene therapy. Diabetes vol. 48:2107-2121, Nov. 1999.*
Liu et al. Intramuscular injectionof plasmid DNA encoding intracellular or secreted glutamic acid decarboxylase causes decreased insulitis in the non-obese diabetic mouse. Gene Therapy and Molecular Biology. vol. 3:197-206, Dec. 1998.*
Von Herrath, M.G. et al.: “In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes” Journal of Immunology, vol. 161, No. 9, Nov. 1, 1998, pp. 5087-5096, XP0000919064 the whole document.
Coon et al., “DNA immunization to prevent autoimmune diabetes”J,. Clin. Invest., 104/2:189-194, 1999.
von Herrath et al., “Role of viruses in type I diabetes”,Seminars in Immunology, 10:87-100, 1998.
von Herrath et al., “How Virus Induces a Rapid or Slow Onset Insulin-Dependent Diabetes Mellitus in a Transgenic Model”,Immunity, 1:231-242, 1994.
von Herrath et al., “Coexpression of B7-1 and Viral (“Self”) Transgenes in Pancreatic β Cells Can Break Peripheral Ignorance and Lead to Spontaneous Autoimmune Diabetes”,Immunity, 3:727-738, 1995.
von Herrath et al., “Oral Insulin Treatment Suppresses Virus-induced Antigen-specific Destruction of β Cells and Prevents Autoimmune Diabetes in Transgenic Mice”,J,. Clin. Invest., 98/6:1324-1331, 1996.
von Herrath and Oldstone, “Interferon-γ Is Essential for Destruction of β Cells and Development of Insulin-dependent Diabetes Mellitus”,J,.Exp. Med., 185/3:531-539, 1997.
von Herrath and Oldstone, “Virus-induced autoimmune disease”,Current Opinion in Immunology, 8/878-885, 1996.
von Herrath and Oldstone, “Pathological Changes in the Islet Milieu Precede Infiltration of Islets and Destruction of β Cells by Autoreactive Lymphocytes in a Transgenic Model of Virus-Induced IDDM”,J,.Autoimmunity, 10:231-239, 1997.
Holz et al., “Disruption of the STAT4 Signaling Pathway Protects from Autoimmune Diabetes While Retaining Antiviral Immune Competence”,J. Immunology, pp. 5374-5382, 1999.
Homann et al., “Autoreactive DC4+T Cells Protect from Autoimmune Diabetes via Bystander Suppression Using the IL-4/Stat6 Pathway”,Immunity, 11:463-472, 1999.
Liu et al., “Intramuscular injection of plasmid DNA encoding intracellular or secreted gultamic acid decarboxylase causes decreased insulitis in the non-obese diabetic mouse,”Gene Ther Mol Biol. 3:197-296, 1998.
DLA Piper Rudnick Gray Cary US LLP
Guzo David
The Scripps Research Institute
LandOfFree
Compositions and methods for the treatment or prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment or prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment or prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3431076